Contact your
Local MSL
Request A Medical Science
Liaison (MSL)

OPSUMIT® (macitentan) video library

Explore an informative video series around the professional and patient perspectives on PAH featuring Lindsay, a patient living with PAH who has been taking OPSUMIT® since 2013.

Individual patient experience may vary. OPSUMIT® has a 9-year long-term safety, tolerability, and survival open-label extension study in patients with PAH.1


Lindsay's path to a PAH specialist

BACK TO TOP

PAH=pulmonary arterial hypertension.
Reference: 1. Souza R, Delcroix M, Galié N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39(9):4374-4390

EXPAND +

+ +